Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 461


Patient-Reported Outcomes in Patients Chronic Viral Hepatitis without Cirrhosis: The Impact of Hepatitis B and C Viral Replication.

Younossi ZM, Stepanova M, Younossi I, Papatheodoridis G, Janssen HLA, Agarwal K, Nguyen MH, Gane E, Tsai N, Nader F.

Liver Int. 2019 Jun 7. doi: 10.1111/liv.14171. [Epub ahead of print]


Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada.

McGivern DR, Lin HS, Wang J, Benzine T, Janssen HLA, Khalili M, Lisker-Melman M, Fontana RJ, Belle SH, Fried MW.

Open Forum Infect Dis. 2019 Apr 9;6(5):ofz175. doi: 10.1093/ofid/ofz175. eCollection 2019 May.


Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B.

van Campenhout MJH, Rijckborst V, Brouwer WP, van Oord GW, Ferenci P, Tabak F, Akdogan M, Pinarbasi B, Simon K, de Knegt RJ, Boonstra A, Janssen HLA, Hansen BE.

J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13117. [Epub ahead of print]


Elevated serum levels of soluble CD14 in HBeAg-positive chronic HBV patients upon Peginterferon treatment are associated with treatment response.

Dou Y, van Montfoort N, van den Bosch A, Janssen HLA, de Man RA, Buschow SI, Woltman AM.

J Viral Hepat. 2019 May 15. doi: 10.1111/jvh.13127. [Epub ahead of print]


Nonalcoholic Fatty Liver Disease in The Rotterdam Study: About Muscle Mass, Sarcopenia, Fat Mass, and Fat Distribution.

Alferink LJM, Trajanoska K, Erler NS, Schoufour JD, de Knegt RJ, Ikram MA, Janssen HLA, Franco OH, Metselaar HJ, Rivadeneira F, Darwish Murad S.

J Bone Miner Res. 2019 May 10. doi: 10.1002/jbmr.3713. [Epub ahead of print]


Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B.

Chang KM, Traum D, Park JJ, Ho S, Ojiro K, Wong DK, Wahed AS, Terrault NA, Khalili M, Sterling RK, Janssen HLA, Shuhart MC, Lau DT, Roberts LR, Johnson GS, Kaplan DE, Betts MR, Lee WM, Lok ASF; Hepatitis B Research Network (HBRN).

PLoS Pathog. 2019 Apr 18;15(4):e1007715. doi: 10.1371/journal.ppat.1007715. eCollection 2019 Apr.


A global scientific strategy to cure hepatitis B.

Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e7.


Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.

Harms MH, van Buuren HR, Corpechot C, Thorburn D, Janssen HLA, Lindor KD, Hirschfield GM, Parés A, Floreani A, Mayo MJ, Invernizzi P, Battezzati PM, Nevens F, Ponsioen CY, Mason AL, Kowdley KV, Lammers WJ, Hansen BE, van der Meer AJ.

J Hepatol. 2019 Apr 11. pii: S0168-8278(19)30228-4. doi: 10.1016/j.jhep.2019.04.001. [Epub ahead of print]


Diet-dependent acid load - the missing link between an animal protein-rich diet and non-alcoholic fatty liver disease?

Alferink LJM, Kiefte-de Jong JC, Erler NS, de Knegt RJ, Hoorn EJ, Ikram MA, Janssen HLA, Metselaar HJ, Franco OH, Murad SD.

J Clin Endocrinol Metab. 2019 Apr 12. pii: jc.2018-02792. doi: 10.1210/jc.2018-02792. [Epub ahead of print]


Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.

Sonneveld MJ, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Liaw YF, Hansen BE, Choi H, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Knegt RJ, Janssen HLA.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):538-544. doi: 10.1016/S2468-1253(19)30087-1. Epub 2019 Apr 9.


Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B.

Di Bisceglie AM, King WC, Lisker-Melman M, Khalili M, Belle SH, Feld JJ, Ghany MG, Janssen HLA, Lau D, Lee WM, Ling SC, Cooper S, Rosenthal P, Schwarz KB, Sterling RK, Teckman JH, Terrault N; Hepatitis B Research Network (HBRN).

J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13104. [Epub ahead of print]


Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell T, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C.

Gastroenterology. 2019 Mar 28. pii: S0016-5085(19)34634-7. doi: 10.1053/j.gastro.2019.03.044. [Epub ahead of print]


Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B.

Liem KS, Yim C, Ying TD, Zanjir WR, Fung S, Wong DK, Shah H, Feld JJ, Hansen BE, Janssen HLA.

Liver Int. 2019 Mar 25. doi: 10.1111/liv.14105. [Epub ahead of print]



Chi H, Peng J, Janssen HLA.

Clin Gastroenterol Hepatol. 2019 Apr;17(5):1001-1002. doi: 10.1016/j.cgh.2018.10.005. No abstract available.


Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues.

Sonneveld MJ, van Oord GW, van Campenhout MJ, De Man RA, Janssen HLA, de Knegt RJ, Boonstra A, van der Eijk AA.

J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13097. [Epub ahead of print]


Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.

Pavlovic V, Yang L, Chan HL, Hou J, Janssen HL, Kao JH, Lampertico P, Peng CY, Piratvisuth T, Thompson AJ, Wedemeyer H, Wei L, Wat C.

Antivir Ther. 2019;24(2):133-140. doi: 10.3851/IMP3304.


Role of Autophagy in Chronic Liver Inflammation and Fibrosis.

Tseng YJ, Dong L, Xu N, Ma W, Weng SQ, Janssen HLA, Wu SD.

Curr Protein Pept Sci. 2019 Mar 5. doi: 10.2174/1389203720666190305165203. [Epub ahead of print]


Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue-induced HBeAg seroconversion.

Van Hees S, Chi H, Hansen B, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Wong D, Sprengers D, Moreno C, Nevens F, Janssen HLA, Vanwolleghem T.

J Viral Hepat. 2019 Jun;26(6):766-769. doi: 10.1111/jvh.13084. Epub 2019 Mar 14. No abstract available.


Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.

Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P.

Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20.


Editorial: identifying candidates for pegylated interferon add-on to entecavir therapy in patients with HBeAg-positive chronic hepatitis B - authors' reply.

Liem KS, Janssen HLA.

Aliment Pharmacol Ther. 2019 Mar;49(5):610-611. doi: 10.1111/apt.15155. No abstract available.


Supplemental Content

Loading ...
Support Center